Both in Pharmaceuticals
Erasca vs Travere Therapeutics
Over the past year ERAS returned +545.5% and TVTX returned +53.6%; their daily moves had a correlation of 0.10.
ERAS +545.5% TVTX +53.6%Growth of $1, one year, split-adjusted
| Metric | ERAS | TVTX |
|---|---|---|
| Price | $14.91 | $52.42 |
| Market cap | $5.21B | $4.94B |
| Today | +1.84% | +6.09% |
| 1 month | +4.3% | −6.4% |
| 6 months | +36.8% | +17.1% |
| Year to date | +300.8% | +37.2% |
| 1 year | +526.5% | +51.8% |
| Revenue growth (YoY) | — | +36.2% |
| Gross margin | — | 98.7% |
| Net margin | — | −23.3% |
| P/E (TTM) | — | — |
| Price / sales | — | 7.6× |
| Net cash | $268.7M | -$131.7M |
| Dividend yield | — | — |
| Volatility (60d) | 59.7% | 37.8% |
| Short % of float | 14.5% | 12.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).